Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:00 AM
Ignite Modification Date:
2025-12-25 @ 12:00 AM
NCT ID:
NCT00002358
Eligibility Criteria:
Inclusion Criteria
Patients must have:
* HIV infection.
* Cutaneous, visceral, or ocular varicella-zoster viral infection.
* Refractory or intolerant to acyclovir or foscarnet therapy.
* Consent of parent or guardian.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
* Inability to take oral capsules or tolerate liquids.
Concurrent Medication:
Excluded:
* 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid.
Patients with the following prior condition are excluded:
History of immediate hypersensitivity to nucleoside analogues.
Prior Medication:
Excluded:
* 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry.
Required:
* Prior acyclovir or foscarnet.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
2 Years
Maximum Age:
17 Years
Study:
NCT00002358
Study Brief:
Protocol Section:
NCT00002358